| 134.84 4.92 (3.79%) | 10-24 14:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 280.32 | 1-year : | 327.41 |
| Resists | First : | 240 | Second : | 280.32 |
| Pivot price | 154.42 |
|||
| Supports | First : | 96.16 | Second : | 7.26 |
| MAs | MA(5) : | 136.99  |
MA(20) : | 118.06 |
| MA(100) : | 229.93 |
MA(250) : | 1216.59 |
|
| MACD | MACD : | 22.7 |
Signal : | 24.5 |
| %K %D | K(14,3) : | 53.5 |
D(3) : | 54.7 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 3403.12 | Low : | 0.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPRB ] has closed above bottom band by 24.7%. Bollinger Bands are 73% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 140.63 - 141.31 | 141.31 - 141.99 |
| Low: | 126.73 - 127.53 | 127.53 - 128.33 |
| Close: | 128.42 - 129.7 | 129.7 - 130.97 |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Wed, 22 Oct 2025
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
Tue, 21 Oct 2025
Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus
Wed, 15 Oct 2025
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Wed, 08 Oct 2025
Spruce Biosciences Announces $50.0 Million Private Placement Financing - Business Wire
Tue, 07 Oct 2025
Why Is Spruce Biosciences Stock (SPRB) Surging Today? - TipRanks
Tue, 07 Oct 2025
Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 375720 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.063e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 900.3 % |
| Return on Equity (ttm) | -65.1 % |
| Qtrly Rev. Growth | 1.3e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -53.88 |
| EBITDA (p.s.) | -1.55968e+007 |
| Qtrly Earnings Growth | -86.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.54 |
| Price to Cash Flow | 14.49 |
| Dividend | 0 |
| Forward Dividend | 5660 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|